Compare ELWT & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELWT | RNTX |
|---|---|---|
| Founded | 2002 | 2001 |
| Country | United States | United States |
| Employees | 34 | 10 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6M | 42.9M |
| IPO Year | N/A | N/A |
| Metric | ELWT | RNTX |
|---|---|---|
| Price | $6.12 | $1.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $10.00 |
| AVG Volume (30 Days) | 39.7K | ★ 114.9K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $167.76 | N/A |
| Revenue Next Year | $22.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.11 | $1.02 |
| 52 Week High | $8.25 | $2.22 |
| Indicator | ELWT | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.22 | 68.31 |
| Support Level | $6.30 | $1.08 |
| Resistance Level | $7.10 | $2.18 |
| Average True Range (ATR) | 0.71 | 0.18 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 58.26 | 89.83 |
Elauwit Connection Inc is a provider of broadband Internet networks for the multifamily and student housing property sector. It designs, installs, operates, and maintains new fiber-optic and WiFi networks throughout each contracted property. Once installed, property owners begin selling Internet connectivity over Elauwit's network directly to their residents at monthly prices and terms of their choosing. Elauwit, in turn, provides all resident activation, onboarding, customer support, and network monitoring and maintenance services in exchange for a fixed monthly fee based on the number of units in the property times a monthly per-unit wholesale price. Its contracts with property owners generally have five to eight-year terms. Geographically, the company mainly operates in the U.S.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.